Revenio Group Corporation: President & CEO Olli-Pekka Salovaara to work temporarily in the US

Revenio Group Corporation Stock Exchange Release 23 March 2015 at
16.30

President & CEO Olli-Pekka Salovaara to work temporarily in the US

The United States is Revenio's most important market area, accounting for over
40% of the Group's net sales. Revenio Group's President & CEO Olli-Pekka
Salovaara will be moving to work in their new location in Raleigh, North
Carolina, to further boost the Group's market position in the US. This temporary
move will have no effect on the Group organization or operating structure, nor
on Revenio's Head Office functions in Vantaa, Finland.

"The United States is the world's largest market for health technology. Through
our presence in this market area we will be able to better support our local
distribution network and our own organization, and make them even better. Icare
has currently 32 independent sales representatives in the US and we intend to
make this network even stronger. Local presence is important also in terms of
moving forward the FDA process. The most important reason for my moving to the
US is to build a personal relationship with the customer base, our distributors
and physicians in decision-making positions," says Mr Salovaara.

"Our objective is solid growth in health technology, and my move to the US
should result in growth and higher market share both in terms of existing and
future products and technologies," he continues.

Revenio Group Corporation
Olli-Pekka Salovaara
CEO

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520 or US
+1-561-413-7559
olli-pekka.salovaara@revenio.fi
www.revenio.fi

Distribution:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy and Oscare Medical Oy, which specializes in osteoporosis screening and
monitoring. In addition, Revenio has identified new growth opportunities
relating to health tech in which common denominators are screening, follow-up
and the global need to make cost savings in health care via preventive measures.
Revenio seeks vigorous growth in health technology, both organically and through
acquisitions and mergers.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
margin for continuing operations standing at 27,5%. The Revenio Group
Corporation is listed on Nasdaq Helsinki.


[HUG#1905528]